Work

Abstract PS5-02-29: Clinical data of DB-1305/BNT325 (TROP2 antibody-drug conjugate [ADC]) in patients (pts) with metastatic triple negative breast cancer (mTNBC): Efficacy and safety data from a phase 1/2 trial

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps5-02-29

Authors: E. Hamilton, D. A. Aysel, M. Yan, C. Wang, H. Yang, J. Shi, W. Xie, H. Wang, Y. Sun, X. Sun, B. Zhang, Q. Yang, Z. Jia, H. Mu, S. Tillmanns, Y. Barbachano, J. Furlanetto, T. Sun

Institutions: Sarah Cannon, Zhengzhou University, Henan Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Affiliated Hospital of Hebei University, Guangxi Medical University, Tumor Hospital of Guangxi Medical University, Shandong Tumor Hospital, Shandong First Medical University, Duality Biotherapeutics, Inc. (China), BioNTech (Germany), Liaoning Cancer Hospital & Institute

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7130691765

Cites:

Cited by:

Related to: